FDA Approves Horizant For Restless Legs Syndrome, Bringing Relief To XenoPort, Revenues To GSK
This article was originally published in The Pink Sheet Daily
Executive Summary
The California biotech likely to get a lifeline, while GSK will benefit from incremental revenues, but the market, including payers, has to yet to be educated.
You may also be interested in...
Deal Watch: Arbor Betting On Building Horizant Commercially As Xenoport Couldn't
Ireland's Jazz pays $1.5bn to acquire Celator and its hotly anticipated leukemia drug, Vyxeos; Spero takes over antibacterial program out-licensed by Vertex; Novartis to copromote Eisai's Lenvima.
Arbor's Bid For XenoPort Likely Driven By Effort To Grow Horizant
With minimal unencumbered pipeline assets to offer, XenoPort's value to Arbor apparently lies in positive sales trends for the modest-selling restless legs and postherpetic neuralgia drug.
Battered XenoPort Holds On For April PDUFA Date For Horizant
XenoPort Inc. is even more focused on the April 6 review deadline for its lead candidate, Horizant, for restless leg syndrome, after its second-string compound came up short in a Phase IIb trial in gastroesophageal reflux disease.